EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC

NCT07637448 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer Non-Small Cell Cancer (NSCLC)
EGFR Activating Mutation
PD-1 Antibody

Interventions

DRUG: EGFR-TKIs Combined with PD-1 Monoclonal Antibody

Sponsor

Nanfang Hospital, Southern Medical University